<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105879">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887262</url>
  </required_header>
  <id_info>
    <org_study_id>COMPASS</org_study_id>
    <nct_id>NCT01887262</nct_id>
  </id_info>
  <brief_title>Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS</brief_title>
  <acronym>COMPASS</acronym>
  <official_title>Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS (COMPASS) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Medical Care Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioimpedance-guided fluid management in peritoneal dialysis patients may provide better
      protection of residual renal function over 1 year period, compared with management guided by
      clinical information alone - such as blood pressure, body weight, and physician's physical
      examination.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>delta GFR</measure>
    <time_frame>baseline and 12th  month</time_frame>
    <safety_issue>No</safety_issue>
    <description>change of glomerular filtration rate from baseline to the 12th month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR</measure>
    <time_frame>at 12th month</time_frame>
    <safety_issue>No</safety_issue>
    <description>glomerular filtration rate measured by urine collection, calculated by the mean of creatinine and urea clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to anuria</measure>
    <time_frame>over 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to the anuric state (urine volume &lt; 100cc/d)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic parameters</measure>
    <time_frame>12 months period</time_frame>
    <safety_issue>No</safety_issue>
    <description>parameters obtained by echocardiographic measurements such as left ventracular mass index (LVMi), E/e' ratio, left vetricular end-diastolic volume (LVEDP), left ventracular ejection fraction (LVEF), left atrial volume indx (LAVI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP</measure>
    <time_frame>12th month</time_frame>
    <safety_issue>No</safety_issue>
    <description>systolic, diastolic blood pressure, pulse pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular event</measure>
    <time_frame>over 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>fatal and nonfatal cardiovascular events - acute myocardial infarction (AMI), stroke, unstable angina, amputation, cardiovascular revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCM parameters</measure>
    <time_frame>baseline and 12th month</time_frame>
    <safety_issue>No</safety_issue>
    <description>parameters measured by body composition monitoring (BCM), such as overhydration(OH), extracellular water (ECW), extracellular-to-intracellular water ratio (ECW/ICW)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Peritoneal Dialysis, Continuous Ambulatory</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BCM-guided fluid management</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluid management based on the clinical information alone</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age bwten 20 and 75

          -  peritoneal dialysis &gt; 4 weeks duration

          -  written consent

          -  daily urine output &gt; 500 ml

        Exclusion Criteria:

          -  subjects who are contraindicated to the bioimpedance measurement (pacemaker insertion
             state, defibrillator state, amputee, prosthesis, metal implants)

          -  pregnant women

          -  subjects who are expected to discontinue peritoneal dialysis with one year

          -  mixed dialysis modality (peritoneal + hemodialysis)

          -  hypoalbuminemic subjects (serum albumin &lt; 3.3 g/dL)

          -  high blood pressure (&gt; 160/100 mmHg despite antihypertensive medications)

          -  severe heart failure (NYHA FC III, or IV)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kook-Hwan Oh, M.D, Ph.D</last_name>
    <phone>82 2 2072 0776</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ki-Young Na, M.D, Ph.D</last_name>
    <phone>82 10 9267 4315</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SuJin Cho</last_name>
      <phone>82 2 2072 0694</phone>
      <email>snuhirb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kook-Hwan Oh, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Van Biesen W, Williams JD, Covic AC, Fan S, Claes K, Lichodziejewska-Niemierko M, Verger C, Steiger J, Schoder V, Wabel P, Gauly A, Himmele R; EuroBCM Study Group. Fluid status in peritoneal dialysis patients: the European Body Composition Monitoring (EuroBCM) study cohort. PLoS One. 2011 Feb 24;6(2):e17148. doi: 10.1371/journal.pone.0017148.</citation>
    <PMID>21390320</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kook-Hwan Oh</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>fluid</keyword>
  <keyword>edema</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
